Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: rarely (96), occasionally (196), seldom (7)

Carotid endarterectomy - patient information

Description: Information about having a carotid endarterectomy
Url: /Media/UHS-website-2019/Patientinformation/Cardiovascular-and-thoracic/Carotid-endarterectomy-1656-PIL.pdf

Endometrial-Dostarlimab

Description: Chemotherapy Protocol GYNACOLOGICAL CANCER Dostarlimab Regimen  Endometrial - Dostarlimab Indication  Dostarlimab is indicated for patients with; - proven histological
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/Dostarlimab.pdf

Avelumab(800mg)

Description: Chemotherapy Protocol BLADDER CANCER AVELUMAB (800mg) Regimen  Bladder Cancer - Avelumab Indication  Avelumab is indicated as monotherapy for the f
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Avelumab800mg.pdf

Managing pain after surgery

Description: pain management after surgery v2.qxp_Layout 1 09/06/2022 12:21 Page 1 Managing pain after your surgery This leaflet explains what you ca
Url: /Media/UHS-website-2019/Docs/Services/Pain/Managing-pain-after-surgery.pdf

Total body irradiation (TBI) - patient information

Description: This factsheet explains what to expect at your TBI treatment appointments.
Url: /Media/UHS-website-2019/Patientinformation/Cancercare/Total-body-irradiation-TBI-1332-PIL.pdf

Durvalumab_14day

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (14 day) Regimen • NSCLC - Durvalumab (14 day) Indication • Stage 3 NSCLC after radical chemoradiotherapy •
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab-14day.pdf

Durvalumab(28day-1500mg)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (28 day – 1500mg) Regimen • NSCLC - Durvalumab (28 day – 1500mg) Indication • D
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab28day-1500mg.pdf

Pembrolizumab2mg/kg

Description: Chemotherapy Protocol LUNG CANCER Pembrolizumab (2mg/kg) Regimen • NSCLC – Pembrolizumab (2mg/kg) Indication • Pembrolizumab is recommended as an option for treating locally advanced
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab2mgkg.pdf

Nivolumab ver 1 (NSCLC)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Nivolumab This regimen may require funding. Regimen NSCLC – Nivolumab Indication Metastat
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Nivolumab-ver-1.pdf

Nivolumab 240mg (NSCLC)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Nivolumab (240mg-14 days) Regimen • NSCLC – Nivolumab (240mg
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Nivolumab-240mg.pdf

361 to 370 of 560

Previous … 35 36 37 38 39 … Next